🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Arkansas › Little Rock

Uji klinis Kanker Paru Non-Sel Kecil di Little Rock, AR

13 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Little Rock (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 2
  • University of Arkansas for Medical Sciences /ID# 272923, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT06568939

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Menerima pesertaFase 3
  • UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06312137

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Menerima pesertaFase 2
  • CARTI Cancer Center, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT03191149

Pan-tumor MRD Study

Menerima pesertaStudi observasional
  • CARTI, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06605404

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Menerima pesertaFase 2
  • Research Site, Little Rock
Usia 18 hingga 95 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05061550

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Menerima pesertaFase 3
  • CARTI Cancer Center ( Site 0006), Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06422143

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Menerima pesertaFase 3
  • University of Arkansas for Medical Sciences, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06500481

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • University of Arkansas, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07444814

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Arkansas for Medical Sciences, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Arkansas for Medical Sciences, Little Rock
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Arkansas for Medical Sciences, Little Rock
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Menerima pesertaStudi observasional
  • Massive Bio SYNERGY-AI site, Little Rock
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di Little Rock

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.